| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 01/09/2003 | US20030008881 Substituted phenylcyclohexanecarboxamides and their use |
| 01/09/2003 | US20030008877 CCR5 antagonists useful for treating AIDS |
| 01/09/2003 | US20030008872 2,3-Diaryl-pyrazolo[1,5-B]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors |
| 01/09/2003 | US20030008868 Compounds useful as anti-inflammatory agents |
| 01/09/2003 | US20030008867 Compounds |
| 01/09/2003 | US20030008865 Xanthine-and phenazone-acesulfame-H complexes having improved taste, process for their preparation and their use |
| 01/09/2003 | US20030008856 Treatment of septic shock |
| 01/09/2003 | US20030008844 Administering formulatin comprising iduronylglycosaminoglycan sulfate and dermatan sulfate or their salts, solvates, hydrates or clathartes for therapy and prophylaxis of inflammatory bowel disease |
| 01/09/2003 | US20030008842 Formulations of adenosine a1 agonists |
| 01/09/2003 | US20030008841 Anti-HCV nucleoside derivatives |
| 01/09/2003 | US20030008840 Methods for treating cancer |
| 01/09/2003 | US20030008834 Compsoitions and methods for treating epithelia and retinal tissue diseases |
| 01/09/2003 | US20030008829 For therapy and prophylaxis of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis, immunomediated inflammatory disorders, such as rheumatoid arthritis, conjunctivitis, psoriasis |
| 01/09/2003 | US20030008822 Use of IL-18 inhibitors for the treatment or prevention of sepsis |
| 01/09/2003 | US20030008820 Methods and products related to FGF dimerization |
| 01/09/2003 | US20030008809 Use of 5-HT (3) receptor antagonists for treating musculoeskeletal diseases |
| 01/09/2003 | US20030008398 Nucleotide sequences coding polypeptide for use in the treatment of autoimmune and inflammatory diseases |
| 01/09/2003 | US20030008293 Detection of polymorphism in preferential nucleotide sequences; obtain cells, extract nucleotide sequences, incubate with probe, detect signal, monitor hybridization pattern |
| 01/09/2003 | US20030008023 Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract |
| 01/09/2003 | US20030008022 Medical effect of jojoba oil |
| 01/09/2003 | US20030008021 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/09/2003 | US20030008008 Fast dissolving orally consumable films |
| 01/09/2003 | US20030008003 Compositions for enhanced absorption of NSAIDs |
| 01/09/2003 | US20030008002 Containing titanium dioxide platelets |
| 01/09/2003 | US20030007992 Zero-order prolonged release coaxial implants |
| 01/09/2003 | US20030007968 Administering bone marrow cells with lymphyocytes removed; then busulfan |
| 01/09/2003 | US20030007958 Mixture of silica, flow control agent and carrier; cyclooxygenase inhibitor, antiinflammatory agents |
| 01/09/2003 | US20030007934 Delivery of stimulants through an inhalation route |
| 01/09/2003 | US20030007933 Delivery of muscle relaxants through an inhalation route |
| 01/09/2003 | US20030005924 Delivery of beta-blockers through an inhalation route |
| 01/09/2003 | CA2452361A1 Use of tyrosine kinase inhibitors for treating autoimmune diseases |
| 01/09/2003 | CA2452200A1 Method for identifying compounds that specifically deplete mast cells |
| 01/09/2003 | CA2452169A1 Use of tyrosine kinase inhibitors for treating inflammatory diseases |
| 01/09/2003 | CA2452105A1 Dibenzocycloheptene compound |
| 01/09/2003 | CA2452092A1 Carbohydrate derivatives |
| 01/09/2003 | CA2452082A1 Extracellular messengers |
| 01/09/2003 | CA2452058A1 Bispecific antibodies that bind to vegf receptors |
| 01/09/2003 | CA2452030A1 Sustained release pharmaceutical composition |
| 01/09/2003 | CA2451955A1 Antibodies to opgl |
| 01/09/2003 | CA2451128A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | CA2451125A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | CA2450722A1 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | CA2450686A1 Substituted 8-arylquinoline pde4 inhibitors |
| 01/09/2003 | CA2450356A1 Bone anabolic compounds and methods of use |
| 01/09/2003 | CA2447280A1 Use of sulodexide for the treatment of inflammatory bowel disease |
| 01/08/2003 | EP1273659A1 Novel g protein-coupled receptor protein and dna thereof |
| 01/08/2003 | EP1273582A1 Heterocyclo-alkylsulfonyl pyrazoles as anti-inflammatory/analgesic agents |
| 01/08/2003 | EP1273580A1 Sulfonyl heteroaryl triazoles as anti-inflammatory and analgesic agents |
| 01/08/2003 | EP1273576A1 Sulfonyl aryl triazoles as anti-inflammatory/analgesic agents |
| 01/08/2003 | EP1273300A2 A stable external preparation containing aspirin |
| 01/08/2003 | EP1273289A1 Pharmaceutical compositions containing ascomycin derivatives |
| 01/08/2003 | EP1273288A1 Pharmaceutical compositions containing rapamycin derivatives |
| 01/08/2003 | EP1272907A2 Compliance tracking method |
| 01/08/2003 | EP1272853A2 Methods for identifying and using amyloid-inhibitory compounds |
| 01/08/2003 | EP1272670A2 Diagnosis of diseases associated with dna adducts |
| 01/08/2003 | EP1272666A1 A functional assay of high-density lipoprotein |
| 01/08/2003 | EP1272641A2 Serine-threonine kinase |
| 01/08/2003 | EP1272638A2 Drug metabolizing enzymes |
| 01/08/2003 | EP1272518A2 Cd20/ige-receptor like molecules and uses thereof |
| 01/08/2003 | EP1272515A2 Immunoregulator |
| 01/08/2003 | EP1272514A1 Dna encoding human vanilloid receptor vr3 |
| 01/08/2003 | EP1272511A2 Molecules associated with human reproduction |
| 01/08/2003 | EP1272506A1 Human aminoacyl-trna synthetase polypeptides useful for the regulation of angiogenesis |
| 01/08/2003 | EP1272505A1 8beta-substituted-11beta-pentyl- and 11beta-hexyl-estra-1,3,5(10)-triene derivatives |
| 01/08/2003 | EP1272504A1 8beta-hydrocarbyl-substituted estratrienes for use as selective estrogens |
| 01/08/2003 | EP1272499A1 Pharmaceutical compositions containing oligosaccharides and preparation thereof |
| 01/08/2003 | EP1272488A2 Tri-aryl-substituted-ethane pde4 inhibitors |
| 01/08/2003 | EP1272487A1 Bicyclic heteroaryl compounds as inhibitors of the interaction between the integrin alpha4beta1 receptor and vcam-1 and/or fibronectin |
| 01/08/2003 | EP1272484A2 Benzoamide piperidine compounds as substance p antagonists |
| 01/08/2003 | EP1272481A1 4-fluoroalkyl-2h-benzopyrans with anti-estrogenic activity |
| 01/08/2003 | EP1272467A1 Cathepsin cysteine protease inhibitors |
| 01/08/2003 | EP1272456A1 Hydrazide and alkoxyamide angiogenesis inhibitors |
| 01/08/2003 | EP1272455A1 Halogenated 2-amino-4, 5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
| 01/08/2003 | EP1272225A2 Lipid-based systems for targeting diagnostic agents |
| 01/08/2003 | EP1272223A1 Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same |
| 01/08/2003 | EP1272222A2 Compositions for drug delivery |
| 01/08/2003 | EP1272221A2 Peptide conjugates for drug delivery |
| 01/08/2003 | EP1272218A2 A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| 01/08/2003 | EP1272201A2 Use of compatible solutes as substances having free radical scavenging properties |
| 01/08/2003 | EP1272200A1 Divided dose therapies with vascular damaging activity |
| 01/08/2003 | EP1272189A1 Inhibition of cyclooxygenase-2 activity |
| 01/08/2003 | EP1272186A1 Therapeutic combinations of antihypertensive and antiangiogenic agents |
| 01/08/2003 | EP1272185A2 Use of quinazoline derivatives as angiogenesis inhibitors |
| 01/08/2003 | EP1272175A2 Il-8 receptor antagonists |
| 01/08/2003 | EP1272173A1 Methods for inhibiting angiogenesis and tumor growth |
| 01/08/2003 | EP1272172A2 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases |
| 01/08/2003 | EP1272169A2 Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia |
| 01/08/2003 | EP1272161A2 Lipid-based drug delivery systems against parasitic infections |
| 01/08/2003 | EP1272160A2 Lipid-based drug delivery systems for topical application |
| 01/08/2003 | EP1123276B1 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them |
| 01/08/2003 | EP1119355B1 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 01/08/2003 | EP1087977B1 Thienodipyridine derivatives, production and use thereof |
| 01/08/2003 | EP1077945B1 Isoquinolines as urokinase inhibitors |
| 01/08/2003 | EP1053239B1 Glucocorticoid-selective anti-inflammatory agents |
| 01/08/2003 | EP1023266B1 Process for making diaryl pyridines useful as cox-2 inhibitors |
| 01/08/2003 | EP0892795B1 Piperidinylpyramidine derivatives |
| 01/08/2003 | EP0859622B1 Extracts of shark cartilage |
| 01/08/2003 | EP0817646B1 Methods of treating inflammation and compositions therefor |
| 01/08/2003 | EP0646012B1 WOUND HEALING AND TREATMENT OF FIBROTIC DISORDERS BY TGFbeta-3 |
| 01/08/2003 | CN1390257A Transfer compounds, the production and the use thereof |